학술논문
Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19
Document Type
article
Author
Jordana Grazziela A. Coelho dos Reis; Geovane Marques Ferreira; Alice Aparecida Lourenço; Ágata Lopes Ribeiro; Camila Pacheco da Silveira Martins da Mata; Patrícia de Melo Oliveira; Daisymara Priscila de Almeida Marques; Linziane Lopes Ferreira; Felipe Alves Clarindo; Murillo Ferreira da Silva; Heitor Portella Póvoas Filho; Nilson Roberto Ribeiro Oliveira, Jr; Maisah Meyhr D’Carmo Sodré; Sandra Rocha Gadelha; George Rego Albuquerque; Bianca Mendes Maciel; Ana Paula Melo Mariano; Mylene de Melo Silva; Renato Fontana; Lauro Juliano Marin; Renata Santiago Alberto Carlos; Amanda Teixeira Sampaio Lopes; Fabrício Barbosa Ferreira; Uener Ribeiro dos Santos; Íris Terezinha Santos de Santana; Hllytchaikra Ferraz Fehlberg; Rachel Passos Rezende; João Carlos T. Dias; Eduardo Gross; Gisele Assis Castro Goulart; Marie Gabriele Santiago; Ana Paula Motta Lavigne de Lemos; Aline O. da Conceição; Carla Cristina Romano; Luciana Debortoli de Carvalho; Olindo Assis Martins Filho; Claudio Almeida Quadros; David L. Morris; Sarah J. Valle
Source
Biomedicine & Pharmacotherapy, Vol 148, Iss , Pp 112753- (2022)
Subject
Language
English
ISSN
0753-3322
Abstract
COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention and cytokine storm, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc®, a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation. Method: Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine analysis using Luminex kit was performed. Results: BromAc® displayed a robust mucolytic effect in a dose dependent manner on COVID-19 sputum ex vivo. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1Ra and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250 µg. Conclusion: These results indicate robust mucolytic and anti-inflammatory effect of BromAc® ex vivo in tracheal aspirates from critically ill COVID-19 patients, indicating its potential to be further assessed as pharmacological treatment for COVID-19.